Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 14% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: mriradiationhighwomenfraction
  Phrases that lowered it: weekshepatitislargetrialpatients
• Sponsor's past termination rate: 22.7% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 27.3% (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Disease area, neurology: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 20 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Sponsor's past trials: 22 (raises risk) · Sponsor's track record
• Responsible party: sponsor (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 23 (raises risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 1 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab NCT01931098 · started 2015 · scored riskier than 56% of active trials completed
• Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma NCT01266031 · started 2011 · scored riskier than 50% of active trials completed
• Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma NCT00761280 · started 2008 · scored riskier than 72% of active trials terminated
• Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas NCT01478321 · started 2011 · scored riskier than 79% of active trials terminated
• An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. NCT01386580 · started 2011 · scored riskier than 83% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.